

Figure 1 displays 16 small plots arranged in a 4x4 grid, showing the relationship between the number of species (S) and the number of individuals (N) for various taxa. The taxa are arranged in rows: Invertebrates, Fish, Birds, and Mammals. The columns represent different methods: Species richness, Species evenness, Species diversity, and Species abundance. Each plot shows a positive correlation between S and N, with the slope of the relationship varying by taxon and method. The y-axis for all plots is 'Number of species' (S) and the x-axis is 'Number of individuals' (N).

[illegible][illegible]

1. General Information 2. Administrative Data 3. Identification 4. Classification 5. Keywords 6. Abstract 7. Summary 8. Conclusions 9. References 10. Appendices 11. Tables 12. Figures 13. Footnotes 14. Index 15. Subject Index 16. Author Index 17. Table of Contents 18. Table of Figures 19. Table of Tables 20. Table of Figures 21. Table of Tables 22. Table of Figures 23. Table of Tables 24. Table of Figures 25. Table of Tables 26. Table of Figures 27. Table of Tables 28. Table of Figures 29. Table of Tables 30. Table of Figures 31. Table of Tables 32. Table of Figures 33. Table of Tables 34. Table of Figures 35. Table of Tables 36. Table of Figures 37. Table of Tables 38. Table of Figures 39. Table of Tables 40. Table of Figures 41. Table of Tables 42. Table of Figures 43. Table of Tables 44. Table of Figures 45. Table of Tables 46. Table of Figures 47. Table of Tables 48. Table of Figures 49. Table of Tables 50. Table of Figures 51. Table of Tables 52. Table of Figures 53. Table of Tables 54. Table of Figures 55. Table of Tables 56. Table of Figures 57. Table of Tables 58. Table of Figures 59. Table of Tables 60. Table of Figures 61. Table of Tables 62. Table of Figures 63. Table of Tables 64. Table of Figures 65. Table of Tables 66. Table of Figures 67. Table of Tables 68. Table of Figures 69. Table of Tables 70. Table of Figures 71. Table of Tables 72. Table of Figures 73. Table of Tables 74. Table of Figures 75. Table of Tables 76. Table of Figures 77. Table of Tables 78. Table of Figures 79. Table of Tables 80. Table of Figures 81. Table of Tables 82. Table of Figures 83. Table of Tables 84. Table of Figures 85. Table of Tables 86. Table of Figures 87. Table of Tables 88. Table of Figures 89. Table of Tables 90. Table of Figures 91. Table of Tables 92. Table of Figures 93. Table of Tables 94. Table of Figures 95. Table of Tables 96. Table of Figures 97. Table of Tables 98. Table of Figures 99. Table of Tables 100. Table of Figures 101. Table of Tables 102. Table of Figures 103. Table of Tables 104. Table of Figures 105. Table of Tables 106. Table of Figures 107. Table of Tables 108. Table of Figures 109. Table of Tables 110. Table of Figures 111. Table of Tables 112. Table of Figures 113. Table of Tables 114. Table of Figures 115. Table of Tables 116. Table of Figures 117. Table of Tables 118. Table of Figures 119. Table of Tables 120. Table of Figures 121. Table of Tables 122. Table of Figures 123. Table of Tables 124. Table of Figures 125. Table of Tables 126. Table of Figures 127. Table of Tables 128. Table of Figures 129. Table of Tables 130. Table of Figures 131. Table of Tables 132. Table of Figures 133. Table of Tables 134. Table of Figures 135. Table of Tables 136. Table of Figures 137. Table of Tables 138. Table of Figures 139. Table of Tables 140. Table of Figures 141. Table of Tables 142. Table of Figures 143. Table of Tables 144. Table of Figures 145. Table of Tables 146. Table of Figures 147. Table of Tables 148. Table of Figures 149. Table of Tables 150. Table of Figures 151. Table of Tables 152. Table of Figures 153. Table of Tables 154. Table of Figures 155. Table of Tables 156. Table of Figures 157. Table of Tables 158. Table of Figures 159. Table of Tables 160. Table of Figures 161. Table of Tables 162. Table of Figures 163. Table of Tables 164. Table of Figures 165. Table of Tables 166. Table of Figures 167. Table of Tables 168. Table of Figures 169. Table of Tables 170. Table of Figures 171. Table of Tables 172. Table of Figures 173. Table of Tables 174. Table of Figures 175. Table of Tables 176. Table of Figures 177. Table of Tables 178. Table of Figures 179. Table of Tables 180. Table of Figures 181. Table of Tables 182. Table of Figures 183. Table of Tables 184. Table of Figures 185. Table of Tables 186. Table of Figures 187. Table of Tables 188. Table of Figures 189. Table of Tables 190. Table of Figures 191. Table of Tables 192. Table of Figures 193. Table of Tables 194. Table of Figures 195. Table of Tables 196. Table of Figures 197. Table of Tables 198. Table of Figures 199. Table of Tables 200. Table of Figures 201. Table of Tables 202. Table of Figures 203. Table of Tables 204. Table of Figures 205. Table of Tables 206. Table of Figures 207. Table of Tables 208. Table of Figures 209. Table of Tables 210. Table of Figures 211. Table of Tables 212. Table of Figures 213. Table of Tables 214. Table of Figures 215. Table of Tables 216. Table of Figures 217. Table of Tables 218. Table of Figures 219. Table of Tables 220. Table of Figures 221. Table of Tables 222. Table of Figures 223. Table of Tables 224. Table of Figures 225. Table of Tables 226. Table of Figures 227. Table of Tables 228. Table of Figures 229. Table of Tables 230. Table of Figures 231. Table of Tables 232. Table of Figures 233. Table of Tables 234. Table of Figures <	
---	--

Variable	Baseline		12 months		24 months		36 months		48 months		60 months		72 months		84 months		96 months		108 months		120 months	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age at baseline (years)	65.4	6.1	66.4	6.1	67.4	6.1	68.4	6.1	69.4	6.1	70.4	6.1	71.4	6.1	72.4	6.1	73.4	6.1	74.4	6.1	75.4	6.1
Age at follow-up (years)																						
Female sex	52.1	5.0	51.8	5.0	51.5	5.0	51.2	5.0	50.9	5.0	50.6	5.0	50.3	5.0	50.0	5.0	49.7	5.0	49.4	5.0	49.1	5.0
Married	68.5	4.8	68.2	4.8	67.9	4.8	67.6	4.8	67.3	4.8	67.0	4.8	66.7	4.8	66.4	4.8	66.1	4.8	65.8	4.8	65.5	4.8
White ethnicity	85.2	3.5	85.1	3.5	85.0	3.5	84.9	3.5	84.8	3.5	84.7	3.5	84.6	3.5	84.5	3.5	84.4	3.5	84.3	3.5	84.2	3.5
High education	72.3	4.2	72.1	4.2	71.9	4.2	71.7	4.2	71.5	4.2	71.3	4.2	71.1	4.2	70.9	4.2	70.7	4.2	70.5	4.2	70.3	4.2
High income	65.4	4.5	65.2	4.5	65.0	4.5	64.8	4.5	64.6	4.5	64.4	4.5	64.2	4.5	64.0	4.5	63.8	4.5	63.6	4.5	63.4	4.5
Smoker	15.6	3.8	15.4	3.8	15.2	3.8	15.0	3.8	14.8	3.8	14.6	3.8	14.4	3.8	14.2	3.8	14.0	3.8	13.8	3.8	13.6	3.8
Drinker	22.3	4.1	22.1	4.1	21.9	4.1	21.7	4.1	21.5	4.1	21.3	4.1	21.1	4.1	20.9	4.1	20.7	4.1	20.5	4.1	20.3	4.1
Comorbidities	35.7	5.2	35.5	5.2	35.3	5.2	35.1	5.2	34.9	5.2	34.7	5.2	34.5	5.2	34.3	5.2	34.1	5.2	33.9	5.2	33.7	5.2
Medication	45.8	4.9	45.6	4.9	45.4	4.9	45.2	4.9	45.0	4.9	44.8	4.9	44.6	4.9	44.4	4.9	44.2	4.9	44.0	4.9	43.8	4.9
Quality of life	55.9	5.5	55.7	5.5	55.5	5.5	55.3	5.5	55.1	5.5	54.9	5.5	54.7	5.5	54.5	5.5	54.3	5.5	54.1	5.5	53.9	5.5
Healthcare costs	12.3	3.2	12.1	3.2	11.9	3.2	11.7	3.2	11.5	3.2	11.3	3.2	11.1	3.2	10.9	3.2	10.7	3.2	10.5	3.2	10.3	3.2
Healthcare utilization	18.4	3.5	18.2	3.5	18.0	3.5	17.8	3.5	17.6	3.5	17.4	3.5	17.2	3.5	17.0	3.5	16.8	3.5	16.6	3.5	16.4	3.5
Healthcare satisfaction	62.5	4.3	62.3	4.3	62.1	4.3	61.9	4.3	61.7	4.3	61.5	4.3	61.3	4.3	61.1	4.3	60.9	4.3	60.7	4.3	60.5	4.3
Healthcare access	78.9	3.7	78.7	3.7	78.5	3.7	78.3	3.7	78.1	3.7	77.9	3.7	77.7	3.7	77.5	3.7	77.3	3.7	77.1	3.7	76.9	3.7
Healthcare equity	85.6	3.1	85.4	3.1	85.2	3.1	85.0	3.1	84.8	3.1	84.6	3.1	84.4	3.1	84.2	3.1	84.0	3.1	83.8	3.1	83.6	3.1
Healthcare quality	92.3	2.8	92.1	2.8	91.9	2.8	91.7	2.8	91.5	2.8	91.3	2.8	91.1	2.8	90.9	2.8	90.7	2.8	90.5	2.8	90.3	2.8
Healthcare safety	98.7	1.5	98.5	1.5	98.3	1.5	98.1	1.5	97.9	1.5	97.7	1.5	97.5	1.5	97.3	1.5	97.1	1.5	96.9	1.5	96.7	1.5

Journal of Interpersonal Violence 28(12)

[illegible]

[illegible]

Name	Age	Time to Event (months)			
		Event	Survival	Recurrence	Death
1. Patient 1 (Male)	65	12	24	36	48
2. Patient 2 (Female)	58	18	30	42	54
3. Patient 3 (Male)	72	6	12	18	24
4. Patient 4 (Female)	61	24	36	48	60
5. Patient 5 (Male)	68	15	27	39	51
6. Patient 6 (Female)	55	30	42	54	66
7. Patient 7 (Male)	70	9	18	27	36
8. Patient 8 (Female)	63	21	33	45	57
9. Patient 9 (Male)	66	11	22	33	44
10. Patient 10 (Female)	59	27	39	51	63
11. Patient 11 (Male)	71	7	14	21	28
12. Patient 12 (Female)	64	19	30	41	52
13. Patient 13 (Male)	69	13	26	39	52
14. Patient 14 (Female)	57	33	45	57	69
15. Patient 15 (Male)	73	5	10	15	20
16. Patient 16 (Female)	62	23	35	47	59
17. Patient 17 (Male)	67	16	32	48	64
18. Patient 18 (Female)	56	36	48	60	72
19. Patient 19 (Male)	74	4	8	12	16
20. Patient 20 (Female)	65	25	37	49	61
21. Patient 21 (Male)	70	10	20	30	40
22. Patient 22 (Female)	60	30	42	54	66
23. Patient 23 (Male)	75	3	6	9	12
24. Patient 24 (Female)	63	22	34	46	58
25. Patient 25 (Male)	68	14	28	42	56
26. Patient 26 (Female)	58	34	46	58	70
27. Patient 27 (Male)	72	8	16	24	32
28. Patient 28 (Female)	61	26	38	50	62
29. Patient 29 (Male)	66	17	34	51	68
30. Patient 30 (Female)	59	31	43	55	67
31. Patient 31 (Male)	71	6	12	18	24
32. Patient 32 (Female)	64	20	32	44	56
33. Patient 33 (Male)	69	11	22	33	44
34. Patient 34 (Female)	57	35	47	59	71
35. Patient 35 (Male)	73	4	8	12	16
36. Patient 36 (Female)	65	25	37	49	61
37. Patient 37 (Male)	70	10	20	30	40
38. Patient 38 (Female)	60	30	42	54	66
39. Patient 39 (Male)	75	3	6	9	12
40. Patient 40 (Female)	63	22	34	46	58
41. Patient 41 (Male)	68	14	28	42	56
42. Patient 42 (Female)	58	34	46	58	70
43. Patient 43 (Male)	72	8	16	24	32
44. Patient 44 (Female)	61	26	38	50	62
45. Patient 45 (Male)	66	17	34	51	68
46. Patient 46 (Female)	59	31	43	55	67
47. Patient 47 (Male)	71	6	12	18	24
48. Patient 48 (Female)	64	20	32	44	56
49. Patient 49 (Male)	69	11	22	33	44
50. Patient 50 (Female)	57	35	47	59	71

Variable	Descriptive Statistics		Univariate Analysis		Multivariate Analysis		p-value
	Mean	SD	OR	95% CI	OR	95% CI	
Age (years)	65.2	10.5	1.05	1.02-1.08	1.03	1.01-1.05	0.001
Gender							0.002
Male	58.5	11.2	1.0		1.0		
Female	66.8	9.8	1.15	1.05-1.26	1.12	1.02-1.23	
Education Level							0.003
High School or less	55.1	12.5	1.0		1.0		
College or more	68.9	8.7	1.25	1.15-1.36	1.22	1.12-1.33	
Marital Status							0.004
Married	62.3	10.1	1.0		1.0		
Single	67.5	9.5	1.18	1.08-1.29	1.15	1.05-1.26	
Divorced	65.8	11.3	1.12	1.02-1.23	1.09	1.00-1.19	
Widowed	69.1	8.9	1.22	1.12-1.33	1.19	1.09-1.30	
Health Insurance							0.005
Medicaid	59.4	13.1	1.0		1.0		
Medicare	66.2	9.3	1.15	1.05-1.26	1.12	1.02-1.23	
Private	68.5	8.5	1.28	1.18-1.39	1.25	1.15-1.36	
Uninsured	61.7	11.8	1.08	0.98-1.19	1.05	0.95-1.16	
Employment Status							0.006
Employed	63.1	10.3	1.0		1.0		
Unemployed	67.3	9.7	1.15	1.05-1.26	1.12	1.02-1.23	
Retired	69.5	8.6	1.25	1.15-1.36	1.22	1.12-1.33	
Disability	65.4	11.4	1.12	1.02-1.23	1.09	1.00-1.19	
Comorbidities							0.007
Diabetes	58.2	12.3	1.0		1.0		
Hypertension	62.5	10.8	1.15	1.05-1.26	1.12	1.02-1.23	
Heart Disease	65.8	9.5	1.25	1.15-1.36	1.22	1.12-1.33	
Stroke	68.1	8.9	1.35	1.25-1.46	1.32	1.22-1.43	
Chronic Kidney Disease	69.4	8.2	1.45	1.35-1.56	1.42	1.32-1.53	
Depression	66.7	9.8	1.18	1.08-1.29	1.15	1.05-1.26	
Anxiety	67.9	9.1	1.22	1.12-1.33	1.19	1.09-1.30	
Substance Use							0.008
Alcohol	64.5	10.5	1.0		1.0		
Drugs	68.2	9.4	1.25	1.15-1.36	1.22	1.12-1.33	
Tobacco	66.1	10.2	1.15	1.05-1.26	1.12	1.02-1.23	
Medication Adherence							0.009
High	63.8	10.1	1.0		1.0		
Low	67.6	9.6	1.18	1.08-1.29	1.15	1.05-1.26	
Healthcare Access							0.010
Close	62.9	10.4	1.0		1.0		
Far	68.3	9.3	1.25	1.15-1.36	1.22	1.12-1.33	
Transportation							0.011
Yes	63.5	10.2	1.0		1.0		
No	67.8	9.7	1.18	1.08-1.29	1.15	1.05-1.26	
Financial Stability							0.012
Stable	64.2	10.3	1.0		1.0		
Unstable	68.6	9.2	1.25	1.15-1.36	1.22	1.12-1.33	
Social Support							0.013
High	63.7	10.1	1.0		1.0		
Low	68.0	9.5	1.25	1.15-1.36	1.22	1.12-1.33	
Quality of Life							0.014
High	64.1	10.2	1.0		1.0		
Low	67.7	9.6	1.18	1.08-1.29	1.15	1.05-1.26	

[illegible][illegible]

[illegible][illegible]

Biomarker	Assay	Sample Size (n)	Prevalence (%)		Sensitivity (%)		Specificity (%)		PPV (%)		NPV (%)	
			Observed	95% CI	Observed	95% CI	Observed	95% CI	Observed	95% CI	Observed	95% CI
Group 1: Liver Cancer Biomarkers												
Alpha-fetoprotein (AFP)												
Observed Prevalence	15.2%	1000	15.2	12.8-17.6	85.4%	82.1-88.7	92.1%	89.5-94.7	88.5%	85.9-91.1	95.8%	93.2-98.4
95% CI	14.5-15.9				84.7-86.1			91.4-92.8			95.1-96.5	
Observed Sensitivity	85.4%				82.1-88.7			89.5-94.7			93.2-98.4	
95% CI	84.7-86.1				81.0-83.2			88.0-91.4			92.5-95.9	
Observed Specificity	92.1%				89.5-94.7			85.9-91.1			91.1-95.8	
95% CI	91.4-92.8				88.0-91.4			84.2-89.6			89.6-94.2	
Observed PPV	88.5%				85.9-91.1			82.1-88.7			78.9-85.4	
95% CI	87.8-89.2				84.2-89.6			80.4-86.8			77.2-82.8	
Observed NPV	95.8%				93.2-98.4			91.1-95.8			89.5-94.7	
95% CI	95.1-96.5				92.5-95.9			89.6-94.2			88.7-93.2	
Group 2: Pancreatic Cancer Biomarkers												
CA19-9												
Observed Prevalence	18.7%	850	18.7	16.3-21.1	78.9%	75.6-82.2	91.5%	88.9-94.1	89.2%	86.6-91.8	96.1%	93.5-98.7
95% CI	18.0-19.4				78.2-80.6			90.8-92.2			95.4-96.8	
Observed Sensitivity	78.9%				75.6-82.2			88.9-94.1			93.5-98.7	
95% CI	78.2-80.6				74.9-79.5			88.2-93.8			92.8-97.5	
Observed Specificity	91.5%				88.9-94.1			86.6-91.8			93.5-98.7	
95% CI	90.8-92.2				88.2-93.8			85.9-91.1			92.8-97.5	
Observed PPV	89.2%				86.6-91.8			82.2-89.5			85.4-93.1	
95% CI	88.5-90.1				85.9-91.1			81.5-88.8			84.7-92.8	
Observed NPV	96.1%				93.5-98.7			91.8-96.1			93.5-98.7	
95% CI	95.4-96.8				92.8-97.5			91.1-95.4			92.8-97.5	
Group 3: Colorectal Cancer Biomarkers												
CEA												
Observed Prevalence	12.5%	920	12.5	10.1-14.9	82.3%	79.0-85.6	93.8%	91.2-96.4	90.1%	87.5-92.7	97.3%	94.7-99.9
95% CI	11.8-13.2				81.6-83.0			93.1-96.1			96.6-98.0	
Observed Sensitivity	82.3%				79.0-85.6			91.2-96.4			94.7-99.9	
95% CI	81.6-83.0				78.3-84.3			90.5-95.1			94.0-98.6	
Observed Specificity	93.8%				91.2-96.4			87.5-92.7			94.7-99.9	
95% CI	93.1-94.5				90.5-95.1			86.8-91.4			94.0-98.6	
Observed PPV	90.1%				87.5-92.7			82.3-89.5			89.5-94.7	
95% CI	89.4-90.8				86.8-91.4			81.6-88.8			88.8-93.4	
Observed NPV	97.3%				94.7-99.9			93.8-97.3			94.7-99.9	
95% CI	96.6-98.0				94.0-98.6			93.1-97.0			94.0-98.6	
Group 4: Prostate Cancer Biomarkers												
PSA												
Observed Prevalence	22.1%	780	22.1	19.7-24.5	71.5%	68.2-74.8	89.7%	87.1-92.3	86.4%	83.8-89.0	98.2%	95.6-100.0
95% CI	21.4-22.8				70.8-73.1			89.0-91.4			97.5-98.9	
Observed Sensitivity	71.5%				68.2-74.8			87.1-92.3			95.6-100.0	
95% CI	70.8-73.1				67.5-75.5			86.4-91.4			94.9-99.1	
Observed Specificity	89.7%				87.1-92.3			83.8-89.0			95.6-100.0	
95% CI	89.0-91.4				86.4-91.4			83.1-88.5			94.9-99.1	
Observed PPV	86.4%				83.8-89.0			78.9-85.4			93.2-98.4	
95% CI	85.7-87.1				83.1-88.5			78.2-85.1			92.5-97.5	
Observed NPV	98.2%				95.6-100.0			98.2-99.9			95.6-100.0	
95% CI	97.5-98.9				94.9-99.1			97.5-99.1			94.9-99.1	

[illegible]

[illegible]

[illegible]

Variable	Sample 1 (N = 100)		Sample 2 (N = 100)		Sample 3 (N = 100)		Sample 4 (N = 100)		Sample 5 (N = 100)	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age	35.2	12.5	36.8	11.2	34.1	13.1	37.5	10.8	33.9	14.2
Gender	0.48	0.50	0.52	0.50	0.45	0.50	0.58	0.50	0.42	0.50
Education	12.1	1.8	11.9	1.7	12.3	1.9	12.0	1.8	11.7	1.7
Income	45.2	15.3	47.8	16.1	43.1	14.2	49.5	17.4	41.9	13.8
Marital Status	0.62	0.49	0.58	0.49	0.65	0.48	0.55	0.49	0.61	0.49
Health Status	0.78	0.41	0.82	0.38	0.75	0.43	0.85	0.35	0.72	0.44
Stress Level	0.65	0.45	0.68	0.46	0.62	0.44	0.70	0.47	0.63	0.45
Life Satisfaction	0.72	0.42	0.75	0.43	0.70	0.41	0.78	0.44	0.71	0.42
Work Engagement	0.85	0.35	0.88	0.32	0.82	0.36	0.90	0.31	0.83	0.34
Job Satisfaction	0.79	0.40	0.81	0.39	0.76	0.41	0.84	0.37	0.77	0.40
Organizational Commitment	0.88	0.32	0.90	0.30	0.85	0.33	0.92	0.29	0.87	0.31
Turnover Intentions	0.15	0.36	0.12	0.33	0.18	0.38	0.10	0.31	0.16	0.35
Work-Life Balance	0.60	0.48	0.63	0.49	0.58	0.47	0.66	0.50	0.59	0.48
Perceived Stress	0.55	0.44	0.58	0.45	0.52	0.43	0.60	0.46	0.53	0.44
Resilience	0.70	0.40	0.73	0.39	0.68	0.41	0.75	0.38	0.69	0.40
Emotional Stability	0.80	0.38	0.82	0.37	0.78	0.39	0.84	0.36	0.79	0.38
Neuroticism	0.20	0.40	0.18	0.38	0.22	0.41	0.16	0.37	0.21	0.39
Extraversion	0.65	0.45	0.68	0.46	0.62	0.44	0.70	0.47	0.63	0.45
Conscientiousness	0.75	0.42	0.78	0.43	0.72	0.41	0.80	0.44	0.73	0.42
Agreeableness	0.60	0.48	0.63	0.49	0.58	0.47	0.66	0.50	0.59	0.48
Openness	0.55	0.44	0.58	0.45	0.52	0.43	0.60	0.46	0.53	0.44

[illegible]

Table 1. Summary of the data sets used in the study									
Data set	Number of subjects	Number of sessions	Number of trials	Number of correct trials	Number of correct trials (%)	Number of correct trials (SD)	Number of correct trials (SE)	Number of correct trials (95% CI)	Number of correct trials (95% CI)
1	10	10	100	80	80.0	1.41	1.41	77.18	82.82
2	10	10	100	80	80.0	1.41	1.41	77.18	82.82
3	10	10	100	80	80.0	1.41	1.41	77.18	82.82
4	10	10	100	80	80.0	1.41	1.41	77.18	82.82
5	10	10	100	80	80.0	1.41	1.41	77.18	82.82
6	10	10	100	80	80.0	1.41	1.41	77.18	82.82
7	10	10	100	80	80.0	1.41	1.41	77.18	82.82
8	10	10	100	80	80.0	1.41	1.41	77.18	82.82
9	10	10	100	80	80.0	1.41	1.41	77.18	82.82
10	10	10	100	80	80.0	1.41	1.41	77.18	82.82
11	10	10	100	80	80.0	1.41	1.41	77.18	82.82
12	10	10	100	80	80.0	1.41	1.41	77.18	82.82
13	10	10	100	80	80.0	1.41	1.41	77.18	82.82
14	10	10	100	80	80.0	1.41	1.41	77.18	82.82
15	10	10	100	80	80.0	1.41	1.41	77.18	82.82
16	10	10	100	80	80.0	1.41	1.41	77.18	82.82
17	10	10	100	80	80.0	1.41	1.41	77.18	82.82
18	10	10	100	80	80.0	1.41	1.41	77.18	82.82
19	10	10	100	80	80.0	1.41	1.41	77.18	82.82
20	10	10	100	80	80.0	1.41	1.41	77.18	82.82
21	10	10	100	80	80.0	1.41	1.41	77.18	82.82
22	10	10	100	80	80.0	1.41	1.41	77.18	82.82
23	10	10	100	80	80.0	1.41	1.41	77.18	82.82
24	10	10	100	80	80.0	1.41	1.41	77.18	82.82
25	10	10	100	80	80.0	1.41	1.41	77.18	82.82
26	10	10	100	80	80.0	1.41	1.41	77.18	82.82
27	10	10	100	80	80.0	1.41	1.41	77.18	82.82
28	10	10	100	80	80.0	1.41	1.41	77.18	82.82
29	10	10	100	80	80.0	1.41	1.41	77.18	82.82
30	10	10	100	80	80.0	1.41	1.41	77.18	82.82
31	10	10	100	80	80.0	1.41	1.41	77.18	82.82
32	10	10	100	80	80.0	1.41	1.41	77.18	82.82
33	10	10	100	80	80.0	1.41	1.41	77.18	82.82
34	10	10	100	80	80.0	1.41	1.41	77.18	82.82
35	10	10	100	80	80.0	1.41	1.41	77.18	82.82
36	10	10	100	80	80.0	1.41	1.41	77.18	82.82
37	10	10	100	80	80.0	1.41	1.41	77.18	82.82
38	10	10	100	80	80.0	1.41	1.41	77.18	82.82
39	10	10	100	80	80.0	1.41	1.41	77.18	82.82

Country	Number of respondents		Age (years)	Gender	Marital status	Education	Occupation	Income (€)	Health status	Smoking status	Alcohol consumption (g/day)	Physical activity (min/week)	Stress (score)	Depression (score)	Anxiety (score)	Life satisfaction (score)	Quality of life (score)
	Male	Female															
Germany	100	100	45.2	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
France	100	100	44.8	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Italy	100	100	45.5	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Spain	100	100	45.1	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
UK	100	100	45.3	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
USA	100	100	45.4	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Canada	100	100	45.6	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Australia	100	100	45.7	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Japan	100	100	45.8	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
China	100	100	45.9	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
India	100	100	46.0	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Brazil	100	100	46.1	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
South Africa	100	100	46.2	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Nigeria	100	100	46.3	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Egypt	100	100	46.4	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Mexico	100	100	46.5	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Argentina	100	100	46.6	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Colombia	100	100	46.7	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Venezuela	100	100	46.8	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Peru	100	100	46.9	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Ecuador	100	100	47.0	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Bolivia	100	100	47.1	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Paraguay	100	100	47.2	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Uruguay	100	100	47.3	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%
Chile	100	100	47.4	50%	50%	12%	15%	25%	30%	10%	15%	20%	10%	10%	10%	10%	10%

[illegible]

Country	Year	Population (millions)	GDP (billion USD)	GDP per capita (USD)	Life expectancy (years)	Infant mortality rate (per 1,000 live births)	Fertility rate (children per woman)	Urban population (%)	Literacy rate (%)	Healthcare expenditure (billion USD)		Healthcare expenditure per capita (USD)	Healthcare expenditure as a share of GDP	
										Government	Private		Government	Private
USA	2019	331.0	21.4	65,800	78.1	7.0	1.7	82.0	99.0	1,100.0	3,300	5.0%	1.0%	
China	2019	1,412.0	14.7	10,400	77.1	10.0	1.6	60.0	95.0	2,000.0	1,400	15.0%	0.5%	
India	2019	1,380.0	3.0	2,100	74.4	25.0	2.0	35.0	74.0	400.0	290	13.0%	0.2%	
Germany	2019	83.0	4.2	50,000	81.0	4.0	1.2	75.0	99.0	1,200.0	14,000	2.8%	0.8%	
Japan	2019	126.0	5.1	40,000	84.4	3.0	1.1	92.0	99.0	1,300.0	10,000	2.5%	0.7%	
UK	2019	67.0	3.0	45,000	81.1	4.0	1.2	88.0	99.0	1,100.0	16,000	2.2%	0.9%	
France	2019	68.0	3.0	44,000	82.4	4.0	1.2	91.0	99.0	1,200.0	17,000	2.1%	0.8%	
Italy	2019	60.0	2.1	35,000	83.7	4.0	1.2	89.0	99.0	1,100.0	18,000	2.0%	0.7%	
Spain	2019	46.0	1.5	32,000	83.5	4.0	1.2	87.0	99.0	1,000.0	22,000	1.9%	0.6%	
Canada	2019	38.0	1.8	48,000	82.7	4.0	1.2	83.0	99.0	1,100.0	29,000	1.8%	0.9%	
Australia	2019	25.0	1.3	55,000	83.7	4.0	1.2	85.0	99.0	1,200.0	48,000	1.7%	1.0%	
South Korea	2019	51.0	1.7	38,000	83.4	4.0	1.2	93.0	99.0	1,300.0	25,000	1.6%	0.8%	
Sweden	2019	10.0	0.5	52,000	83.7	4.0	1.2	90.0	99.0	1,400.0	35,000	1.5%	0.9%	
Norway	2019	5.4	0.4	55,000	82.7	4.0	1.2	88.0	99.0	1,500.0	28,000	1.4%	1.0%	
Denmark	2019	5.6	0.4	53,000	82.7	4.0	1.2	87.0	99.0	1,600.0	29,000	1.3%	0.9%	
Netherlands	2019	17.0	0.9	48,000	82.1	4.0	1.2	92.0	99.0	1,700.0	27,000	1.2%	0.8%	
Belgium	2019	11.0	0.7	43,000	82.1	4.0	1.2	91.0	99.0	1,800.0	26,000	1.1%	0.7%	
Austria	2019	9.0	0.5	50,000	82.1	4.0	1.2	90.0	99.0	1,900.0	21,000	1.0%	0.6%	
Switzerland	2019	8.5	0.8	80,000	83.4	4.0	1.2	89.0	99.0	2,000.0	24,000	0.9%	0.5%	
Portugal	2019	10.0	0.2	25,000	82.1	4.0	1.2	86.0	99.0	1,000.0	10,000	0.8%	0.4%	
Greece	2019	11.0	0.2	22,000	80.0	4.0	1.2	84.0	99.0	900.0	8,000	0.7%	0.3%	
Ireland	2019	4.7	0.3	45,000	82.7	4.0	1.2	86.0	99.0	1,100.0	24,000	0.6%	0.4%	
Poland	2019	38.0	0.4	11,000	78.0	4.0	1.2	78.0	99.0	800.0	2,100	0.5%	0.2%	
Czechia	2019	4.7	0.2	25,000	78.0	4.0	1.2	78.0	99.0	700.0	15,000	0.4%	0.1%	
Slovakia	2019	5.4	0.2	22,000	78.0	4.0	1.2	78.0	99.0	600.0	11,000	0.3%	0.1%	
Hungary	2019	10.0	0.2	22,000	78.0	4.0	1.2	78.0	99.0	500.0	5,000	0.2%	0.1%	
Slovenia	2019	2.1	0.1	48,000	82.7	4.0	1.2	86.0	99.0	1,000.0	24,000	0.1%	0.0%	

Case	Time to first hospitalization		Time to second hospitalization		Time to third hospitalization		Time to fourth hospitalization		Time to fifth hospitalization		Time to death	
	Median (days)	95% CI	Median (days)	95% CI	Median (days)	95% CI	Median (days)	95% CI	Median (days)	95% CI		
1	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
2	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
3	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
4	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
5	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
6	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
7	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
8	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
9	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
10	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
11	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
12	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
13	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
14	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
16	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
17	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
18	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
19	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
20	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
21	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
22	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
23	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
24	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
25	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
26	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
27	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
28	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
29	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
30	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
31	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15	10	5-15
32	10	5-15	10	5-15	10	5-15	10					

[illegible]

[illegible]

1. **Introduction**
This document provides a comprehensive overview of the project's objectives, scope, and the methodology employed for data analysis. It is intended for stakeholders and team members involved in the project.

2. **Objectives**
The primary objectives of this project are to analyze the data, identify trends, and provide actionable insights to improve the overall performance of the system.

3. **Scope**
The project scope is limited to the analysis of data collected from the system over the past six months. It does not include the development of new features or the implementation of changes.

4. **Methodology**
The methodology used for data analysis involves a combination of statistical techniques and machine learning algorithms. The data is first cleaned and preprocessed, then analyzed using various models to identify patterns and trends.

5. **Results**
The analysis results show a significant increase in system performance over the past six months. The data indicates that the system is now able to handle a higher volume of requests with improved response times.

6. **Conclusion**
In conclusion, the project has successfully achieved its objectives. The data analysis has provided valuable insights into the system's performance, which can be used to inform future improvements and optimizations.

7. **Recommendations**
Based on the analysis results, the following recommendations are made: continue to monitor the system's performance, implement the suggested improvements, and conduct regular audits to ensure the system remains optimized.

8. **Appendix**
The appendix contains additional data and charts that support the findings of the analysis. It includes a detailed breakdown of the data by category and a series of line graphs showing trends over time.

9. **References**
The following references are cited in this document: [1] Smith, J. (2020). Data Analysis Techniques. [2] Doe, A. (2019). Machine Learning for Data Analysis. [3] Johnson, B. (2018). System Performance Optimization.

10. **Disclaimer**
The information provided in this document is for informational purposes only and should not be used as a basis for making decisions. The data is subject to change and the analysis is based on the current state of the system.

Table 1: Summary of the data set									
Variable	Unit	Mean	Std. Dev.	Min.	Max.	Q1	Q3	Median	Mode
Age	Years	35.2	12.5	18	65	25	45	30	35
Gender	Male/Female	0.45/0.55	0.50/0.50	0/1	1/0	0/1	1/0	0/1	0/1
Income	Dollars	50,000	20,000	10,000	100,000	30,000	70,000	45,000	50,000
Education	Years	12.5	1.5	9	16	11	14	12	12
Marital Status	Married/Single	0.60/0.40	0.49/0.51	0/1	1/0	0/1	1/0	0/1	0/1
Health Status	Good/Bad	0.70/0.30	0.45/0.55	0/1	1/0	0/1	1/0	0/1	0/1
Occupation	Various	1.2	0.8	0	3	0	2	1	1
Religion	Various	1.5	0.5	0	3	0	2	1	1
Political Affiliation	Various	1.8	0.6	0	4	0	3	1	1
Home Ownership	Owned/Rent	0.55/0.45	0.50/0.50	0/1	1/0	0/1	1/0	0/1	0/1
Vehicle Ownership	Owned/No	0.65/0.35	0.48/0.52	0/1	1/0	0/1	1/0	0/1	0/1
Travel Frequency	Times/Year	10	5	0	20	5	15	10	10
Spending Habits	Dollars/Year	1,000	500	0	2,000	500	1,500	1,000	1,000
Life Satisfaction	Scale 1-5	3.5	0.8	1	5	2	4	3	3
Stress Levels	Scale 1-5	2.5	0.7	1	5	1	3	2	2
Work-Life Balance	Scale 1-5	3.0	0.9	1	5	2	4	3	3
Community Involvement	Scale 1-5	2.0	0.6	1	5	1	3	2	2
Environmental Awareness	Scale 1-5	3.0	0.8	1	5	2	4	3	3
Health Consciousness	Scale 1-5	4.0	0.5	3	5	3	4	4	4
Financial Literacy	Scale 1-5	2.5	0.7	1	5	1	3	2	2
Emotional Stability	Scale 1-5	3.0	0.8	1	5	2	4	3	3
Resilience	Scale 1-5	3.5	0.9	1	5	2	4	3	3
Optimism	Scale 1-5	3.0	0.7	1	5	2	4	3	3
Empathy	Scale 1-5	3.5	0.8	1	5	2	4	3	3
Self-Esteem	Scale 1-5	3.0	0.7	1	5	2	4	3	3
Life Purpose	Scale 1-5	3.5	0.9	1	5	2	4	3	3
Meaning in Life	Scale 1-5	3.0	0.8	1	5	2	4	3	3
Existential Well-being	Scale 1-5	3.5	0.9	1	5	2	4	3	3
Transcendental Well-being	Scale 1-5	3.0	0.7	1	5	2	4	3	3
Overall Well-being	Scale 1-5	3.5	0.8	1	5	2	4	3	3

1. General Information									
2. Financial Data									
3. Operational Data									
4. Environmental Data									
5. Social Data									
6. Governance Data									
7. Risk Data									
8. Compliance Data									
9. Summary									
10. Appendix									
11. Index									
12. Glossary									
13. Bibliography									
14. Acknowledgments									
15. Contact Information									
16. Disclaimer									
17. Notes									
18. Revision History									
19. Approval									
20. Distribution									
21. Footer									
22. Page Numbers									
23. Table of Contents									
24. Index									
25. Glossary									
26. Bibliography									
27. Acknowledgments									
28. Contact Information									
29. Disclaimer									
30. Notes									
31. Revision History									
32. Approval									
33. Distribution									
34. Footer									
35. Page Numbers									
36. Table of Contents									
37. Index									
38. Glossary									
39. Bibliography									
40. Acknowledgments									
41. Contact Information									
42. Disclaimer									
43. Notes									
44. Revision History									
45. Approval									
46. Distribution									
47. Footer									
48. Page Numbers									
49. Table of Contents									
50. Index									
51. Glossary									
52. Bibliography									
53. Acknowledgments									
54. Contact Information									
55. Disclaimer									
56. Notes									
57. Revision History									
58. Approval									
59. Distribution									
60. Footer									
61. Page Numbers									
62. Table of Contents									
63. Index									
64. Glossary									
65. Bibliography									
66. Acknowledgments									
67. Contact Information									
68. Disclaimer									
69. Notes									
70. Revision History									
71. Approval									
72. Distribution									
73. Footer									
74. Page Numbers									
75. Table of Contents									
76. Index									
77. Glossary									
78. Bibliography									
79. Acknowledgments									
80. Contact Information									
81. Disclaimer									
82. Notes									
83. Revision History									
84. Approval									
85. Distribution									
86. Footer									
87. Page Numbers									
88. Table of Contents									
89. Index									
90. Glossary									
91. Bibliography									
92. Acknowledgments									
93. Contact Information									
94. Disclaimer									
95. Notes									
96. Revision History									
97. Approval									
98. Distribution									
99. Footer									
100. Page Numbers									
101. Table of Contents									
102. Index									
103. Glossary									
104. Bibliography									
105. Acknowledgments									
106. Contact Information									
107. Disclaimer									
108. Notes									
109. Revision History									
110. Approval									
111. Distribution									
112. Footer									
113. Page Numbers									
114. Table of Contents									
115. Index									
116. Glossary									
117. Bibliography									
118. Acknowledgments									
119. Contact Information									
120. Disclaimer									
121. Notes									
122. Revision History									
123. Approval									
124. Distribution									
125. Footer									
126. Page Numbers									
127. Table of Contents									
128. Index									

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	52
--	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	----

Section 1: General Information									
Project Details		Client Information		Contract Details		Financial Summary		Compliance & Notes	
Project ID	001-2024-001	Client Name	ABC Corporation	Contract No.	12345	Budget (USD)	500,000	Compliance Status	Compliant
Project Name	Website Redesign	Contact Person	John Doe	Start Date	2024-01-15	Actual Cost (USD)	480,000	Notes	Minor delays in content delivery.
Project Manager	Jane Smith	Phone	+1 555 123 4567	End Date	2024-03-31	Variance (USD)	20,000		
Project Status	In Progress	Email	j.doe@abc.com						
Section 2: Project Scope & Deliverables									
Project Scope					Deliverables				
Scope Description	Redesign of the corporate website to improve user experience and mobile responsiveness.				Deliverable 1	Deliverable 2	Deliverable 3	Deliverable 4	Deliverable 5
Key Features	New layout, improved navigation, SEO optimization, mobile app integration.				Website Design	Content Migration	SEO Audit	Mobile App Dev	Testing & Deployment
Exclusions	Hardware procurement, server hosting, third-party API integration.								
Acceptance Criteria	All features must be functional, content must be accurate, and the site must be mobile-responsive.								
Section 3: Resource Allocation & Schedule									
Resource Allocation			Project Schedule			Milestone Tracking			
Resource Name	Resource ID	Allocation %	Task Name	Start Date	End Date	Milestone 1	Milestone 2	Milestone 3	Milestone 4
Jane Smith	PM-001	100%	Project Kick-off	2024-01-15	2024-01-15	Completed	Completed	Completed	Completed
John Doe	BA-002	50%	Requirements Gathering	2024-01-15	2024-02-01	In Progress	Not Started	Not Started	Not Started
Emily White	QA-003	25%	Design Review	2024-02-01	2024-02-01	Not Started	Not Started	Not Started	Not Started
Michael Brown	DEV-004	75%	Development	2024-02-01	2024-03-15	Not Started	Not Started	Not Started	Not Started
Sarah Green	TEST-005	50%	Testing	2024-03-15	2024-03-31	Not Started	Not Started	Not Started	Not Started
Section 4: Financials & Budget									
Budget Breakdown					Financial Performance				
Category	Sub-category	Amount (USD)	Percentage	Notes	Actual Cost	Budget	Variance	Forecast	Comments
Personnel	Salaries	250,000	50%		240,000	250,000	10,000	250,000	Under budget.
Personnel	Benefits	50,000	10%		50,000	50,000	0	50,000	On track.
Personnel	Travel	10,000	2%		10,000	10,000	0	10,000	On track.
Materials	Software Licenses	30,000	6%		30,000	30,000	0	30,000	On track.
Materials	Hardware	20,000	4%		20,000	20,000	0	20,000	On track.
Materials	Travel	10,000	2%		10,000	10,000	0	10,000	On track.
Overhead	Office Space	20,000	4%		20,000	20,000	0	20,000	On track.
Overhead	Utilities	10,000	2%		10,000	10,000	0	10,000	On track.
Overhead	Insurance	10,000	2%		10,000	10,000	0	10,000	On track.
Overhead	Other	10,000	2%		10,000	10,000	0	10,000	On track.
Section 5: Risk Management & Compliance									
Risk Management					Compliance & Audit				
Risk ID	Risk Description	Impact	Probability	Response	Audit Area	Findings	Recommendations	Resolution Status	Resolution Date
R001	Scope Creep	High	Medium	Control	Scope Management	Minor deviations	Implement change control	Resolved	2024-02-15
R002	Resource Availability	Medium	High	Mitigate	Resource Management	Resource shortage	Reallocate resources	In Progress	2024-03-01
R003	Technical Debt	Low	Low	Monitor	Technical Debt	Minor issues	Refactor code	Not Started	2024-04-01
R004	Security Vulnerabilities	High	Low	Prevent	Security Audit	No findings	Regular updates	Completed	2024-03-10
R005	Legal Compliance	Medium	Medium	Ensure	Legal Review	Minor non-compliance	Update terms of service	In Progress	2024-03-20
Section 6: Project Summary & Recommendations									
Project Summary					Recommendations				
Project Overview	The project is progressing well, with most deliverables completed on time and within budget.								

Year	2010										2011										2012										2013										2014										2015										2016										2017										2018										2019										2020										2021										2022										2023										2024										2025										2026										2027										2028										2029										2030										2031										2032										2033										2034										2035										2036										2037										2038										2039										2040										2041										2042										2043										2044										2045										2046										2047										2048										2049										2050										2051										2052										2053										2054																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar

[illegible]

[illegible]

[illegible]

Variable	Descriptive statistics		Normality tests		Heteroscedasticity tests		Linearity tests		Autocorrelation tests		Multicollinearity tests	
	Mean	SD	Shapiro-Wilk	Q-Q	White	White	Wald	Wald	Durbin-Watson	Durbin-Watson	VIF	Tolerance
Dependent variable	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Independent variable	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Control variable	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Interaction variable	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Quadratic term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Cubic term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Quartic term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Quintic term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Twelfth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Thirteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fourteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fifteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventeenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Twelfth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Thirteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fourteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fifteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventeenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Twelfth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Thirteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fourteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fifteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventeenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Twelfth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Thirteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fourteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fifteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventeenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Twelfth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Thirteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fourteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fifteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventeenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Twelfth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Thirteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fourteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fifteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventeenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Twelfth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Thirteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fourteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fifteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventeenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Twelfth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Thirteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fourteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Fifteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Sixteenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Seventeenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eighth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Ninth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Tenth degree term	1.00	0.00	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999
Eleventh degree term	1.00	0.00	0.999	0.99								

[illegible]

Category	Sub-category	Value	Unit
Operating Expenses	Salaries	100	100
	Benefits	20	20
	Travel	10	10
	Office Supplies	5	5
	Utilities	10	10
	Depreciation	10	10
	Insurance	10	10
	Other	10	10
Total Operating Expenses		175	

Category	Sub-category	Value	Unit
Operating Expenses	Salaries	100	100
	Benefits	20	20
	Travel	10	10
	Office Supplies	5	5
	Utilities	10	10
	Depreciation	10	10
	Insurance	10	10
	Other	10	10
Total Operating Expenses		175	

Category	Sub-category	Value	Unit
Operating Expenses	Salaries	100	100
	Benefits	20	20
	Travel	10	10
	Office Supplies	5	5
	Utilities	10	10
	Depreciation	10	10
	Insurance	10	10
	Other	10	10
Total Operating Expenses		175	

Category	Sub-category	Value	Unit
Operating Expenses	Salaries	100	100
	Benefits	20	20
	Travel	10	10
	Office Supplies	5	5
	Utilities	10	10
	Depreciation	10	10
	Insurance	10	10
	Other	10	10
Total Operating Expenses		175	

Category	Sub-category	Value	Unit
Operating Expenses	Salaries	100	100
	Benefits	20	20
	Travel	10	10
	Office Supplies	5	5
	Utilities	10	10
	Depreciation	10	10
	Insurance	10	10
	Other	10	10
Total Operating Expenses		175	

Category	Sub-category	Value	Unit
Operating Expenses	Salaries	100	100
	Benefits	20	20
	Travel	10	10
	Office Supplies	5	5
	Utilities	10	10
	Depreciation	10	10
	Insurance	10	10
	Other	10	10
Total Operating Expenses		175	

